The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
EVERSANA unveiled Health Strategies Insights by EVERSANA, a comprehensive market access research and insights portfolio to help life science innovators make more informed decisions.
Walgreens Boots Alliance Inc. will pay $269.2 million to settle two whistleblower lawsuits accusing the pharmacy chain of civil fraud for overbilling federal healthcare programs for over a decade.
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.
Johnson & Johnson raised U.S. prices on around two dozen prescription drugs, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among the company’s top-selling products.
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
Biogen Inc.’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said.
A unit of Johnson & Johnson will pay $360 million to resolve an investigation into the company’s financial support of a charity that helped Medicare patients cover out-of-pocket drug costs.
Merck & Co. Inc. raised U.S. prices on five of the company’s drugs in November 2018 by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.
The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, will propose requiring companies to include the price of Rx medicines in TV ads.